Submit IND for TransCon IL-2 b/g
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 11 Jan 2021
- Due
- 30 Sep 2021
- Delivered
- Q3 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The company expects to submit an IND or similar for TransCon IL-2 b/g in the third quarter of 2021.”
What we found
Evidence strength A What the grades mean
The company initiated the IL ßeliege Phase 1/2 clinical trial for TransCon IL-2 ß/g, which implies the IND submission occurred, as the trial was underway by the third quarter of 2021.
-
A Ascendis Pharma A/S 6-K filed 2021-11-10
“Initiated IL ßeliege (“I’ll Believe”) Trial, a Phase 1/2 clinical trial to evaluate TransCon IL-2 ß/g in patients with advanced cancer.” ✓ confirmed on the page
Market reaction: the shares moved -1.9% against the S&P 500 over the three sessions around the disclosure (9 Nov 2021 to 12 Nov 2021). What this measures
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory filing
- Indicative materiality
- Medium rules
- Action
- Submit
- Deliverable
- IND for TransCon IL-2 b/g
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Ascendis Pharma A/S? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ASND-021528 · Corrections policy